insulin pre-treatment — Competitive Intelligence Brief

insulin pre-treatment (insulin pre-treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Metabolic/Endocrinology.

marketed Insulin receptor Metabolic/Endocrinology Small molecule

Target snapshot

insulin pre-treatment (insulin pre-treatment) — University of Minnesota. Insulin pre-treatment prepares the body to better utilize insulin by improving insulin sensitivity and glucose uptake before therapeutic intervention.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
insulin pre-treatment TARGET	insulin pre-treatment	University of Minnesota	marketed		Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.